Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress

Stock Track03-19

Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a positive corporate update.

The clinical-stage biotech reported a revenue of $9.8 million for 2025, substantially beating the FactSet consensus estimate of $5.9 million. Furthermore, its net loss per share narrowed to $0.34, which was better than the estimated loss of $0.37 and an improvement from the $0.36 loss per share in the prior year. The company also ended the year with a strong cash position of $319.8 million.

Investor sentiment was further bolstered by updates on the company's lead program, TSHA-102 for Rett syndrome. Taysha reported dosing multiple patients in its pivotal REVEAL trial, receiving FDA clearance to initiate the ASPIRE trial, and reaching written alignment with the FDA on key manufacturing and regulatory strategies to support a planned Biologics License Application (BLA) submission. The company stated it is on track to complete dosing in both key trials in the second quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162677975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162677975","market":"us","top_or_hot":-1,"title":"Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress","media":"Stock Track","content":"<p>Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a positive corporate update.</p>\n<p>The clinical-stage biotech reported a revenue of $9.8 million for 2025, substantially beating the FactSet consensus estimate of $5.9 million. Furthermore, its net loss per share narrowed to $0.34, which was better than the estimated loss of $0.37 and an improvement from the $0.36 loss per share in the prior year. The company also ended the year with a strong cash position of $319.8 million.</p>\n<p>Investor sentiment was further bolstered by updates on the company's lead program, TSHA-102 for Rett syndrome. Taysha reported dosing multiple patients in its pivotal REVEAL trial, receiving FDA clearance to initiate the ASPIRE trial, and reaching written alignment with the FDA on key manufacturing and regulatory strategies to support a planned Biologics License Application (BLA) submission. The company stated it is on track to complete dosing in both key trials in the second quarter of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-19 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a positive corporate update.</p>\n<p>The clinical-stage biotech reported a revenue of $9.8 million for 2025, substantially beating the FactSet consensus estimate of $5.9 million. Furthermore, its net loss per share narrowed to $0.34, which was better than the estimated loss of $0.37 and an improvement from the $0.36 loss per share in the prior year. The company also ended the year with a strong cash position of $319.8 million.</p>\n<p>Investor sentiment was further bolstered by updates on the company's lead program, TSHA-102 for Rett syndrome. Taysha reported dosing multiple patients in its pivotal REVEAL trial, receiving FDA clearance to initiate the ASPIRE trial, and reaching written alignment with the FDA on key manufacturing and regulatory strategies to support a planned Biologics License Application (BLA) submission. The company stated it is on track to complete dosing in both key trials in the second quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSHA","symbol_name":"Taysha Gene Therapies, Inc.","start_time":0,"source_url":"","article_id":"1162677975","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162677975","pubTimestamp":1773923933,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc."},"translate_title":"个股追踪|Taysha Gene Therapies盘前大涨6.52%因盈利超预期和临床进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1},"content_text":"Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a positive corporate update.\nThe clinical-stage biotech reported a revenue of $9.8 million for 2025, substantially beating the FactSet consensus estimate of $5.9 million. Furthermore, its net loss per share narrowed to $0.34, which was better than the estimated loss of $0.37 and an improvement from the $0.36 loss per share in the prior year. The company also ended the year with a strong cash position of $319.8 million.\nInvestor sentiment was further bolstered by updates on the company's lead program, TSHA-102 for Rett syndrome. Taysha reported dosing multiple patients in its pivotal REVEAL trial, receiving FDA clearance to initiate the ASPIRE trial, and reaching written alignment with the FDA on key manufacturing and regulatory strategies to support a planned Biologics License Application (BLA) submission. The company stated it is on track to complete dosing in both key trials in the second quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162677975","isCrawlerRequest":true}